Javascript must be enabled to continue!
Figure S3 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
View through CrossRef
<p>Additional example of patient experiencing immune-related pseudoprogression (PsP)</p>
American Association for Cancer Research (AACR)
Benjamin M. Ellingson
John Sampson
Achal Singh Achrol
Manish K. Aghi
Krystof Bankiewicz
Chencai Wang
Martin Bexon
Steven Brem
Andrew Brenner
Sajeel Chowdhary
John R. Floyd
Seunggu Han
Santosh Kesari
Dina Randazzo
Michael A. Vogelbaum
Frank Vrionis
Miroslaw Zabek
Nicholas Butowski
Melissa Coello
Nina Merchant
Fahar Merchant
Title: Figure S3 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Description:
<p>Additional example of patient experiencing immune-related pseudoprogression (PsP)</p>.
Related Results
Data from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Data from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
<div>AbstractPurpose:<p>The current study compared the standard response assessment in neuro-oncology (RANO), immunotherapy RANO (iRANO), and modified RANO (mRANO) crit...
Investigating the role of the apelinergic system in glioblastoma
Investigating the role of the apelinergic system in glioblastoma
<p>Elucidating the molecular signalling circuitry that underpins the pathogenesis of cancers is critical to understanding and developing effective treatment paradigms for can...
Figure S5 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Figure S5 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
<p>Correlation between duration of clinical benefit (DOCB) and overall survival (OS) for the standard RANO, iRANO, and mRANO criteria. (A) Correlation between radiographic DO...
Figure S5 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Figure S5 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
<p>Correlation between duration of clinical benefit (DOCB) and overall survival (OS) for the standard RANO, iRANO, and mRANO criteria. (A) Correlation between radiographic DO...
Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
Background:
Glioblastoma (GBM) is the most common malignant brain tumor and carries a dismal prognosis. Attempts to develop biologically targeted therapies are challenging as the ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Figure S4 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Figure S4 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
<p>Correlation between mRANO-defined PFS and OS excluding patients with PFS > 120 days. (top) Correlation between radiographic PFS using the mRANO criteria applied to loca...

